25 results for “biomarker validation”. Showing 25 of 39,449.
Validation of biomarkers of aging.
biomarkers of aging should be validated before their translation to the clinic
Overview of Alzheimer's Disease Neuroimaging Initiative and future clinical trials.
validate biomarkers for clinical trials while sharing all data and biofluid
Emerging role of epigenetic mechanisms in glaucoma and their translational potential.
biomarkers for diagnosis and prognosis. Future efforts are needed to validate
Translating neurofilament light chain testing into clinical practice: a multidisciplinary implementation roadmap.
validated biomarker of neuroaxonal injury across multiple neurological conditions, including
Update on biomarkers in neuromyelitis optica.
biomarkers for patients with seronegative NMO have yet to be defined and validated
Parkinson's Disease: Biomarkers for Diagnosis and Disease Progression.
biomarker validation and use, while also highlighting promising improvements. It emphasizes
PDK1 Mediates NOTCH1-Mutated Head and Neck Squamous Carcinoma Vulnerability to Therapeutic PI3K/mTOR Inhibition.
biomarker-driven targeted therapy. Although the PI3K/mTOR pathway is frequently altered in HNSCC, the disease has modest clinical response rates to PI3K/mTOR inhibitors and lacks validated
Biomarker discovery in hepatocellular carcinoma (HCC) for personalized treatment and enhanced prognosis.
biomarker validation, standardization, integration into clinical practice, and cost-related
Blood and cerebrospinal fluid biomarker changes in patients with HIV-associated neurocognitive impairment treated with lithium: analysis from a randomised placebo-controlled trial.
biomarkers validated as predictors of mild cognitive impairment and progression
Sepsis and the Liver.
validating biomarkers, and conducting clinical trials to enable personalized therapies
Mild cognitive impairment in multiple system atrophy: a brain network disorder.
validated biomarkers as basis for early diagnosis and future adequate
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
validated biomarkers to identify which patients will benefit from dual
Magnetic resonance spectroscopy reveals oral Lactobacillus promotion of increases in brain GABA, N-acetyl aspartate and glutamate.
validated biomarkers of brain activity and function, glutamate+glutamine (Glx) and total
Peripheral nerve repair: innovations and future directions.
validated biomarkers for monitoring nerve regeneration. Overcoming these obstacles will
Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies.
validated biomarkers exist. However, advances in research have addressed the issues
Postoperative cognitive dysfunction and neurodegeneration: From inflammation to precision medicine.
biomarker validation, individualized prevention, and long-term cognitive monitoring to address
Updates on Parkinson's Disease.
biomarker validation across ethnic cohorts (30% variability in α-synuclein
A bibliometric analysis of alpha-synuclein in Parkinson's disease from 2015 to 2024.
biomarker validation, and targeted therapies to advance personalized medicine in PD.
Gene therapy for Parkinson's disease: current landscape, translational challenges, and future directions.
optimization, and validated biomarkers will enable precision, stage‑specific interventions.
Decoding Alzheimer's disease through down syndrome: insights from a genetically defined population.
biomarker validation, refine clinical trial design, and inform personalized treatment
Cognitive Deficits After Stroke.
validated biomarkers. These 5 state of the art summaries are sure
A Framework for Identifying Serum Exosomal Lipid Biomarkers in Alzheimer's Disease.
biomarkers. However, a standardized framework for their systematic development is lacking. We propose a structured three-phase approach comprising discovery, analytical validation
Can maternal metformin protect the developing fetal brain?
biomarkers was validated in a second set of individuals undergoing
A natural history study to track brain and spinal cord changes in individuals with Friedreich's ataxia: TRACK-FA study protocol.
validated, sensitive biomarkers of pharmacodynamic response in affected tissue and disease
Urinary TYROBP and HCK as genetic biomarkers for non-invasive diagnosis and therapeutic targeting in IgA nephropathy.
biomarkers were validated in both a test cohort and an external